Brainstorm Cell Therapeutics Stock Investor Sentiment

BCLI Stock  USD 1.73  0.02  1.17%   
Under 61% of Brainstorm Cell's investor base is looking to short. The analysis of the overall investor sentiment regarding Brainstorm Cell Therapeutics suggests that many traders are alarmed. Brainstorm Cell's investing sentiment shows overall attitude of investors towards Brainstorm Cell Therapeutics.
  

Brainstorm Cell Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Brainstorm Cell can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at hawaiinewsnow.com         
SHAREHOLDER ALERT The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a...
news
over a year ago at news.google.com         
Brainstorm Cell Therapeutics to Meet with FDA for ... - TipRanks
Google News at Macroaxis
over a year ago at businesswire.com         
BCLI INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Brainstorm Cell Therapeutics Inc....
businesswire News
over a year ago at businesswire.com         
BCLI INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Brainstorm Cell Therapeutics Inc....
businesswire News
over a year ago at benzinga.com         
SHAREHOLDER ALERT Levi Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Act...
benzinga news
over a year ago at finance.yahoo.com         
BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase ...
Yahoo News
over a year ago at hawaiinewsnow.com         
SHAREHOLDER ALERT The Law Offices of Vincent Wong Remind Brainstorm Cell Investors of a Lead Plainti...
news
over a year ago at news.google.com         
2023-11-19 NDAQBCLI Press Release Brainstorm Cell ... - Stockhouse Publishing
Google News at Macroaxis
over a year ago at prnewswire.com         
SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell T...
prnewswire News
over a year ago at benzinga.com         
BRAINSTORM ONGOING DEADLINE ALERT Faruqi Faruqi Securities Litigation Partner James Wilson Encourage...
benzinga news
over a year ago at benzinga.com         
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure C...
benzinga news
over a year ago at finance.yahoo.com         
BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia
Yahoo News
over a year ago at hawaiinewsnow.com         
ROSEN, A LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel ...
news
over a year ago at benzinga.com         
Glancy Prongay Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ...
benzinga news
over a year ago at benzinga.com         
SHAREHOLDER ALERT The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a...
benzinga news
Far too much social signal, news, headlines, and media speculation about Brainstorm Cell that are available to investors today. That information is available publicly through Brainstorm media outlets and privately through word of mouth or via Brainstorm internal channels. However, regardless of the origin, that massive amount of Brainstorm data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Brainstorm Cell news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Brainstorm Cell relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Brainstorm Cell's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Brainstorm Cell alpha.

Brainstorm Cell Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Uri Yablonka of 13333 shares of Brainstorm Cell at 0.75 subject to Rule 16b-3
09/16/2024
2
BrainStorm announces reverse stock split - Investing.com
09/26/2024
3
Acquisition by Chaim Lebovits of 22000 shares of Brainstorm Cell at 0.228 subject to Rule 16b-3
09/30/2024
4
Acquisition by Chaim Lebovits of 1836 shares of Brainstorm Cell at 3.4272 subject to Rule 16b-3
10/01/2024
5
Disposition of 9600 shares by Patlis Alla of Brainstorm Cell at 9.51 subject to Rule 16b-3
10/10/2024
6
Acquisition by Chaim Lebovits of 135000 shares of Brainstorm Cell at 0.3753 subject to Rule 16b-3
10/11/2024
7
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn Phase 3b Trial Manufacturing - Yahoo Finance
11/11/2024
8
Acquisition by Arbel Irit of 25333 shares of Brainstorm Cell at 0.75 subject to Rule 16b-3
11/12/2024
9
ARMISTICE CAPITAL, LLC Expands Stake in Brainstorm Cell Therapeutics Inc
11/15/2024
10
BrainStorm Strengthens Exosome Patent Portfolio Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology
12/03/2024

Complementary Tools for Brainstorm Stock analysis

When running Brainstorm Cell's price analysis, check to measure Brainstorm Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainstorm Cell is operating at the current time. Most of Brainstorm Cell's value examination focuses on studying past and present price action to predict the probability of Brainstorm Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainstorm Cell's price. Additionally, you may evaluate how the addition of Brainstorm Cell to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Fundamental Analysis
View fundamental data based on most recent published financial statements
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years